RENOVORX INC
RNXTNASDAQ🏆 #4185 by market capEarnings Nov 5US Equity
$1.46▲ $0.03 (+2.10%)
Latest quoteTrack RNXT
Get earnings, price moves & breaking news on Telegram
24h▲ 2.1%
7d▲ 14.5%
14d▲ 21.2%
30d▼ 7.0%
ytd▲ 72.9%
1y▲ 39.7%
🏦Market Cap
$66M
Small Cap
📈Revenue Growth (YoY)
2511.6%
High Growth
📊Gross Margin
84.4%
High
💵FCF Margin
-604.1%
Thin
⚖️P/S Ratio
31.7x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $1.46 – $1.51
- 52-Week Range
- $0.70 – $2.59
- Volume (shares)
- 4,147
- Avg Volume (shares)
- —
- Shares Outstanding
- 45.1M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $909,000
- P/E Ratio
- -4.4
- P/S Ratio
- 31.7x
- EPS (TTM)
- $-0.26
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +58.6%
RENOVORX INC
RNXTFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▲ +2511.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.9%▼ −29.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▲ +14.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▲ +20.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
35.3M▲ +58.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▼ −$64K YoY
StockOtter · stockotter.spaceAbout RENOVORX INC
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.